Sleep health A large share of DSIP studies on sleep health have been animal studies, but a few human trials took place in the 1980s
Related Read: 14 Peptides Are About to Become Legal Again What This Means for Your Health What the science says about peptide stacking as a category 1) Combination trials are the exception, not the rule For many popular peptides, we have: mechanistic arguments small studies (sometimes in narrow contexts) preclinical work We rarely have: well-powered, long-term human trials on the combination hard outcomes (function, cardiometabolic endpoints, durability, safety) 2) Stacking amplifies the two biggest risks in this space Quality risk (variable purity, contamination, labeling issues) Physiology risk (more pathways affected, more unintended effects) 3) The GH/IGF-1 axis is where stacking gets most clinically delicate CJC-1295 has human data showing it raises GH/IGF-1
Analytical testing confirms high purity for both peptides, assay content verified at Ipamorelin 5.68 mg and CJC-1295 (MOD GRF 1-29) 5.74 mg, with endotoxin levels below 0.001 EU/mg
Hydration & Co-factors - IV fluids and B-complex vitamins help restore micronutrients used in metabolic pathways
